Gilteritinib global price

Gilteritinib is a targeted therapy drug used to treat a specific type of leukemia, a mutated subtype of the FLT3 gene in acute myeloid leukemia (Acute Myeloid Leukemia, AML).

Giritinib is currently on the market in China, but it is not included in medical insurance. If patients need it, they can go to the hospital to buy it at their own expense, but the price is very high, about about 35,000 yuan. For specific prices, please consult the local hospital pharmacy.

Foreign original drugs of gilitinib are even more expensive. For example, the Hong Kong version of the original drug costs about 90,000 yuan, and the European version of the original drug costs more than 200,000 yuan, which is simply unaffordable for ordinary patients. There are already foreign generic drugs of Giritinib on the market, mainly Laos generic drugs. The price is about four to five thousand yuan, which is relatively cheap. In terms of drug ingredients, the ingredients of domestic and foreign original gilitinib drugs are basically the same as those of generic drugs.

AML is a hematological malignancy in which abnormal leukemia cells in the bone marrow proliferate rapidly, affecting the normal hematopoietic process. FLT3gene mutations are relatively common in AML patients, accounting for about 30% of cases. This mutation leads to abnormal activation of FLT3 receptor tyrosine kinase, stimulating the growth and differentiation of leukemia cells and worsening the disease.

The mechanism of action of giritinib is to prevent the excessive proliferation of leukemia cells by inhibiting the activity ofFLT3 receptor tyrosine kinase. This makes giritinib an effective drug for the treatment of AML patients with FLT3 gene mutations.